Daiichi Sankyo Hires Merck KGaA Reps To Market Prasugrel In France
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has taken on workers at the French subsidiary of Germany's Merck KGaA to promote its prasugrel anticlotting drug in France this year. Daiichi Sankyo also plans to acquire from Merck the right to market its blood pressure and blood sugar drugs in France. Daiichi's Efient anticlotter is to be promoted in France by 200 of Merck's sales representatives. (Click here for more - a subscription may be required